An open-label study of the effects of intraoperative double filtration plasmapheresis and adoptive immunotherapy with liver allograft derived lymphocytes combination therapy for hepatitis C recurrence after living donor liver transplantatio
Phase 1
- Conditions
- chronic hepatitis C
- Registration Number
- JPRN-UMIN000008754
- Lead Sponsor
- Hiroshima University Hospital, Department of surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
The following patients must be excluded. 1)Recipients with fluminant hepatitis 2)ABO blood type incompatible recipients 3)Recipients of re-transplantation 4)Recipients of deceased donor liver transplantation 5)Patients with the past history of severe shock reactions to any therapy using extracorporeal circulation. 6)Patients who have un-controlable heart disease 7)Patients who are participated in other clinical study within 3 months. 8)Patients who are during pregnancy, lactation expectant, and desiring future fertility. 9)Patients who are judged inappropriate for the clinical trial by doctors. 10)Patients with the past history of severe allergic reactions to nafamostat mesilate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of antivirus activity (recurrence rate of HCV RNA) of DFPP and adoptive immunotherapy combination therapy
- Secondary Outcome Measures
Name Time Method 1.Evaluation of virus reduction effect by DFPP and adoptive immunotherapy combination therapy 2.Adverse effects of DFPP and adoptive immunotherapy combination therapy